哪些标志物最能指导两阶段翻修关节置换术治疗假体周围感染时的再植入时机?一项系统评价与Meta分析
该系统评价与Meta分析纳入12篇文章、1047例患者,评估血清、滑液、组织及影像学标志物预测两阶段翻修关节置换术再植入时机的诊断准确性;组织培养、滑液多形核中性粒细胞百分比和滑液培养诊断性能相对较高,但每个合并分析仅2至3项研究,结论受限;作者认为无单一标志物足以确认感染控制,当前采用多种工具而非单一标志物的做法至关重要。
要点
- 组织培养敏感度0.82、特异度0.91、诊断比值比46.87,诊断性能相对较高。
- 滑液多形核中性粒细胞百分比敏感度0.77、特异度0.74、诊断比值比11.27。
- 滑液培养敏感度0.64、特异度0.96、诊断比值比27.07。
核心结论
- Meta分析提示没有单一标志物优于其他所有标志物,且任一标志物单独使用时可能不足以确认两阶段方案第一阶段后的感染控制。
- 因此,当前采用多种工具而非单一标志物的做法至关重要。
- 此外,必须开展进一步研究,以便利用多项研究进行合并分析来确定再植入的理想标志物。
研究设计与样本
- 检索MEDLINE、EMBASE、OVID和Cochrane数据库,纳入提供髋和/或膝关节再植入预测准确性敏感度和特异度值的文章。
- 最终纳入12篇文章,包含1047例患者的数据。
- 根据诊断方法将标志物分为血清学、滑液、组织和诊断影像四大类,共检查12项参数。
- 使用QUADAS-2独立分析每篇文章的偏倚风险和适用性,采用Cochran Q检验计算统计异质性,α=0.10为异质性显著。
- 证据等级为III级,诊断性研究。
主要发现
- 组织培养敏感度0.82(0.72-0.90)、特异度0.91(0.89-0.95)、诊断比值比46.87(95%CI 22.03-99.69)。
- 滑液多形核中性粒细胞百分比敏感度0.77(0.46-0.95)、特异度0.74(0.67-0.81)、诊断比值比11.27(95%CI 2.89-43.61)。
- 滑液培养敏感度0.64(0.52-0.74)、特异度0.96(0.93-0.98)、诊断比值比27.07(95%CI 2.55-288.00)。
- ESR敏感度0.56(0.40-0.72)、特异度0.60(0.53-0.66)、诊断比值比2.41(95%CI 0.60-9.72);CRP敏感度0.53(0.39-0.67)、特异度0.72(0.66-0.78)、诊断比值比2.25(95%CI 0.09-4.63);滑液白细胞计数敏感度0.37(0.19-0.58)、特异度0.49(0.41-0.57)、诊断比值比0.94(95%CI 0.06-14.74)。
- QUADAS-2评估的四个领域中偏倚风险和适用性担忧均较低。
关键数值与推荐
- 组织培养:敏感度0.82(0.72-0.90)、特异度0.91(0.89-0.95)、诊断比值比46.87(95%CI 22.03-99.69)。
- 滑液多形核中性粒细胞百分比:敏感度0.77(0.46-0.95)、特异度0.74(0.67-0.81)、诊断比值比11.27(95%CI 2.89-43.61)。
- 滑液培养:敏感度0.64(0.52-0.74)、特异度0.96(0.93-0.98)、诊断比值比27.07(95%CI 2.55-288.00)。
- ESR:敏感度0.56(0.40-0.72)、特异度0.60(0.53-0.66)、诊断比值比2.41(95%CI 0.60-9.72)。
- CRP:敏感度0.53(0.39-0.67)、特异度0.72(0.66-0.78)、诊断比值比2.25(95%CI 0.09-4.63);滑液白细胞计数:敏感度0.37(0.19-0.58)、特异度0.49(0.41-0.57)、诊断比值比0.94(95%CI 0.06-14.74)。
临床怎么用
- 作者认为,当前采用多种工具而非单一标志物的做法至关重要。
- 作者认为,必须开展进一步研究,以便利用多项研究进行合并分析来确定再植入的理想标志物。
局限性
- 仅2至3项研究可用于每个合并分析,限制了结果的解读。
- 需要进一步研究以便利用多项研究进行合并分析来确定再植入的理想标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is no consensus on the appropriate marker to use when deciding to perform reimplantation after two-stage exchange arthroplasty for periprosthetic joint infection (PJI). QUESTIONS/PURPOSES: What tests provide acceptable diagnostic value to guide appropriate timing of reimplantation in two-stage exchange arthroplasty for PJI? METHODS: A search of online databases (MEDLINE, EMBASE, OVID, and Cochrane database) was performed containing articles that provided sensitivity and specificity values for accuracy for predicting reimplantation of the hip and/or knee. Twelve articles were included for final analysis, which included data from 1047 patients. Data that described the diagnostic accuracy of markers for reimplantation were evaluated and categorized into four main entities according to diagnostic method (serologic, synovial, tissue, and diagnostic imaging). Twelve parameters were examined, including serum erythrocyte sedimentation (ESR) rate, serum C-reactive protein (CRP), serum white blood cell (WBC) count, synovial fluid Gram stain, synovial fluid culture, synovial fluid sonication culture, synovial fluid WBC, synovial fluid polymorphonucleocyte percentage (PMN%), tissue Gram stain, tissue culture, positron emission tomography scan, and leukocyte scan. Each of the included articles was independently analyzed for risk of bias and applicability by using QUADAS-2. Statistical heterogeneity was calculated by using the Cochran Q test, and an α of 0.10 was considered significant for heterogeneity. RESULTS: Tissue culture (sensitivity 0.82 [0.72-0.90], specificity 0.91 [0.89-0.95], diagnostic odds ratio (DOR) 46.87 [95% confidence interval {CI}, 22.03-99.69], synovial fluid PMN% (sensitivity 0.77 [0.46-0.95], specificity 0.74 [0.67-0.81], DOR 11.27 [95% CI, 2.89-43.61]), and synovial fluid culture (sensitivity 0.64 [0.52-0.74], specificity 0.96 [0.93-0.98], DOR 27.07 [95% CI, 2.55-288.00]) showed relatively high diagnostic performance. Other parameters had poorer diagnostic accuracy: ESR (sensitivity 0.56 [0.40-0.72], specificity 0.60 [0.53-0.66], DOR 2.41 [95% CI, 0.60-9.72), CRP (sensitivity 0.53 [0.39-0.67], specificity 0.72 [0.66-0.78], DOR 2.25 [95% CI, 0.09-4.63), and synovial fluid WBC count (sensitivity 0.37 [0.19-0.58], specificity 0.49 [0.41-0.57], DOR 0.94 [95% CI, 0.06-14.74). However, interpretation is limited, because only two to three studies were available for each pooled analysis. Both risks of bias and applicability concerns were low in the four domains assessed in QUADAS-2. CONCLUSIONS: This meta-analysis suggests that no single marker was superior to all the others, and none (when used alone) is likely sufficient to confirm control of infection after the first stage of a two-stage protocol for PJI. Therefore, the current approach using multiple tools rather than a single marker is essential. Additionally, further studies must be conducted so that pooled analysis can be performed using multiple studies to determine ideal markers for reimplantation. LEVEL OF EVIDENCE: Level III, diagnostic study.
引用
- Lee YS, Fernando N, Koo KH, et al. What Markers Best Guide the Timing of Reimplantation in Two-stage Exchange Arthroplasty for PJI? A Systematic Review and Meta-analysis. Clin Orthop Relat Res. 2018. PMID: 30794241. doi:10.1097/01.blo.0000534680.87622.43
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。